N
NVO

Natixis’s Novo Nordisk NVO Stock Holding History

Natixis’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.7M Buy
2,005,285
+1,159,987
+137% +$55M 0.26% 51
2025
Q4 		$43M Buy
845,298
+462,211
+121% +$23.6M 0.15% 94
2025
Q3 		$21.3M Buy
383,087
+354,425
+1,237% +$20.7M 0.1% 180
2025
Q2 		$1.98M Buy
28,662
+3,745
+15% +$255K 0.01% 492
2025
Q1 		$1.71M Sell
24,917
-2,881
-10% -$238K 0.01% 465
2024
Q4 		$2.39M Buy
27,798
+25,192
+967% +$2.72M 0.01% 438
2024
Q3 		$310K Buy
2,606
+2,420
+1,301% +$323K ﹤0.01% 679
2024
Q2 		$26.6K Sell
186
-5,717
-97% -$758K ﹤0.01% 809
2024
Q1 		$758K Buy
5,903
+5,207
+748% +$620K ﹤0.01% 565
2023
Q4 		$72K Sell
696
-803
-54% -$79.4K ﹤0.01% 799
2023
Q3 		$136K Buy
+1,499
New +$132K ﹤0.01% 756
2022
Q2 		– Sell
-3,798
Closed -$211K – 1292
2022
Q1 		$211K Buy
3,798
+90
+2% +$4.62K ﹤0.01% 1106
2021
Q4 		$208K Buy
+3,708
New +$201K ﹤0.01% 1172
2019
Q2 		– Sell
-24,140
Closed -$628K – 856
2019
Q1 		$628K Buy
24,140
+5,092
+27% +$125K ﹤0.01% 644
2018
Q4 		$439K Sell
19,048
-396
-2% -$8.8K ﹤0.01% 592
2018
Q3 		$458K Buy
19,444
+5,526
+40% +$135K ﹤0.01% 641
2018
Q2 		$321K Buy
13,918
+5,326
+62% +$127K ﹤0.01% 752
2018
Q1 		$212K Buy
8,592
+476
+6% +$12.5K ﹤0.01% 834
2017
Q4 		$218K Buy
+8,116
New +$206K ﹤0.01% 772
2017
Q3 		– Sell
-18,430
Closed -$395K – 1331
2017
Q2 		$395K Sell
18,430
-27,082
-60% -$546K ﹤0.01% 570
2017
Q1 		$780K Buy
45,512
+7,522
+20% +$131K 0.01% 433
2016
Q4 		$681K Buy
37,990
+16,850
+80% +$305K 0.01% 496
2016
Q3 		$440K Buy
21,140
+7,722
+58% +$191K 0.01% 446
2016
Q2 		$361K Buy
+13,418
New +$368K 0.01% 349

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Natixis's NVO Position: Q1 2026 in Review

Natixis increased its Novo Nordisk (NVO) stake by 137% in Q1 2026, buying an estimated $55M and bringing the position to 2,005,285 shares worth $73.7M. The position accounts for 0.26% of the portfolio, ranked #51.

Natixis first reported a position in NVO in Q2 2016 and has held it in 24 quarters since. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Natixis held 2,005,285 shares of Novo Nordisk worth $73.7M as of Q1 2026.
  • Natixis bought 1,159,987 Novo Nordisk shares in Q1 2026, an estimated $55M.
  • Novo Nordisk made up 0.26% of Natixis's portfolio in Q1 2026, its #51 holding.
  • Natixis first reported a position in Novo Nordisk in Q2 2016 and has held it in 24 quarters since.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.